Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1

Table 2 Mean Change from Baseline in Bone Turnover Biomarkers at Week 52 and 104

	Baseline, Mean (SD)	Week 52, Mean change (SD)	Week 104, Mean change (SD)
Anabolic biomarkers
Osteocalcin (ug/L)	n = 99	n = 95	n = 71
Osteocalcin (ug/L)	21.84 (7.56)	1.53 (6.58)	−0.39 (7.13)
Bone specific alkaline phosphatase (U/L)	n = 100	n = 96	n = 73
Bone specific alkaline phosphatase (U/L)	25.01 (8.24)	9.07 (12.89)	−2.66 (6.54)
Procollagen type 1 N-terminal propeptide (ug/L)	n = 99	n = 95	n = 71
Procollagen type 1 N-terminal propeptide (ug/L)	50.76 (20.80)	−1.81 (15.98)	1.79 (21.97)
Procollagen-1 carboxy-terminal peptide (ug/L)	n = 100	n = 96	n = 73
Procollagen-1 carboxy-terminal peptide (ug/L)	107.25 (46.83)	−5.73 (47.13)	10.04 (51.53)
Bone resorption biomarkers
Type I collagen C-telopeptides (ug/L)	n = 99	n = 94	n = 71
Type I collagen C-telopeptides (ug/L)	0.42 (0.20)	−0.01 (0.15)	−0.03 (0.14)
Other biomarkers
Sclerostin (pmol/L)	n = 73	n = 63	n = 52
Sclerostin (pmol/L)	21.66 (8.17)	0.05 (6.90)	2.38 (6.52)
Osteoprotegerin (pmol/L)	n = 98	n = 93	n = 71
Osteoprotegerin (pmol/L)	4.13 (1.50)	−0.91 (1.20)	0.49 (1.53)

Data presented as observed
Analysis included total number of patients who had baseline BMD plus at least one post-baseline lumbar spine BMD value (at Week 52 or 104)
n number of evaluable patients for each parameter at a particular visit, SD standard deviation

ISSN: 1471-2474